Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

The oral, selective factor D inhibitor vemircopan has shown no evidence of benefit in the treatment of adult patients with acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis in a phase 2 trial.

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

19 Jun 2026

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Combination therapy with oral spironolactone and low-dose oral minoxidil appears safe and tolerable among adult females with hair loss, reports a study. However, those using one or more blood pressure (BP)-altering medications are at increased risk of hypotension-related symptoms.

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

19 Jun 2026

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026 bởi

A recent study comparing dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, with orforglipron, an oral nonpeptide glucagon-like peptide-1 (GLP-1) receptor agonist (RA), has found superior glycaemic control and weight loss with the latter.

Orforglipron superior to dapagliflozin in metformin-resistant T2D

19 Jun 2026

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026 bởi

The use of mazdutide among adults with obesity results in a clinically significant weight reduction and improvements in cardiometabolic risk factors, with an acceptable safety profile, as shown in the phase 3 GLORY-2 trial presented at ADA 2026.

Mazdutide cuts weight in adults with obesity, T2D

19 Jun 2026

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026 bởi

In a post hoc analysis of the phase III MAESTRO-NASH trial presented at ADA 2026, systemic thyroid function remained stable with resmetirom, supporting its extrahepatic safety in individuals with metabolic dysfunction-associated steatohepatitis (MASH).

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

19 Jun 2026

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

19 Jun 2026

In the treatment of patients with chronic obstructive pulmonary disease (COPD), the investigational dual phosphodiesterase (PDE) 3 and 4 inhibitor TQC3721 helps improve lung function, according to a phase 2 PACER-II study.

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

19 Jun 2026

Satralizumab cuts relapse risk in MOGAD

19 Jun 2026 bởi

Satralizumab reduces the risk of relapse by 68 percent in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), as shown in the phase III METEOROID study presented at AAN 2026.

Satralizumab cuts relapse risk in MOGAD

19 Jun 2026

Fluvoxamine wins, metformin disappoints in long COVID fatigue

19 Jun 2026 bởi

The antidepressant fluvoxamine reduces long COVID fatigue, whereas the antidiabetic agent metformin fails to outperform placebo in the randomized REVIVE-TOGETHER trial.

Fluvoxamine wins, metformin disappoints in long COVID fatigue

19 Jun 2026

Bằng chứng thực tế cho thấy nirsevimab ưu thế trong việc phòng ngừa RSV ở trẻ nhũ nhi

18 Jun 2026

Virus hợp bào hô hấp (RSV) vẫn là nguyên nhân hàng đầu dẫn đến nhập viện và gây nhiễm trùng đường hô hấp dưới (NTHHD) nặng ở trẻ nhũ nhi trên toàn thế giới. Trong những năm gần đây, hai chiến lược dự phòng miễn dịch được áp dụng để phòng ngừa RSV cho trẻ nhũ nhi là tiêm vắc xin RSVpreF cho phụ nữ mang thai (PNMT) để trẻ hưởng miễn dịch thụ động từ mẹ và kháng thể đơn dòng tác dụng kéo dài nirsevimab cung cấp trực tiếp kháng thể bảo vệ cho trẻ nhũ nhi.

Bằng chứng thực tế cho thấy nirsevimab ưu thế trong việc phòng ngừa RSV ở trẻ nhũ nhi

18 Jun 2026

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026 bởi

For individuals with type 2 diabetes (T2D) that is inadequately controlled by diet and exercise alone, once-weekly administration of the triple hormone receptor agonist retatrutide helps improve glycaemic control, and this benefit is accompanied by substantial weight reduction, as shown in the phase III TRANSCEND-T2D-1 study.

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

18 Jun 2026

Tin tức & Cập nhật

Xem bài viết Đa khoa

Xem

Chuyên ngành:

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Vemircopan for generalized myasthenia gravis misses mark in phase 2 study

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Is spironolactone combined with low-dose minoxidil safe for hair loss in women?

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Orforglipron superior to dapagliflozin in metformin-resistant T2D

Mazdutide cuts weight in adults with obesity, T2D

Mazdutide cuts weight in adults with obesity, T2D

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

MAESTRO-NASH updates validate extrahepatic safety of resmetirom

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Novel dual PDE3/PDE4 inhibitor shows promise in COPD

Satralizumab cuts relapse risk in MOGAD

Satralizumab cuts relapse risk in MOGAD

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Fluvoxamine wins, metformin disappoints in long COVID fatigue

Bằng chứng thực tế cho thấy nirsevimab ưu thế trong việc phòng ngừa RSV ở trẻ nhũ nhi

Bằng chứng thực tế cho thấy nirsevimab ưu thế trong việc phòng ngừa RSV ở trẻ nhũ nhi

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D

Triple hormone receptor agonist delivers glucose-lowering, weight loss benefits in T2D